Efficacy and safety of diacerein in patients with knee osteoarthritis

Diacerein (D) belongs to a class of symptomatic slow-acting agents, has an original mechanism of action, and is widely used as a diseasemodifying antirheumatic drug to treat osteoarthritis (OA) in Russia and many countries of the world. The ability of the drug to affect the main symptoms and progression of OA has been shown in a number of well-organized clinical trials.

Objective: to evaluate the efficacy and safety of D in patients with knee OA.

Patients and methods. An open-label trial evaluating the efficacy and safety of D (diaflex) in patients with knee OA was conducted in accordance with the multicenter program «Osteoarthrosis: Assessment of Progression in Real Clinical Practice». The trial included 80 patients of both sexes with Stage II–III knee OA; mean age, 60.8±6.8 years (47–75 years); mean body mass index, 31.8±5.9 kg/m2; disease duration, 10.3±5.7 years (2–30 years). The duration of the trial was 9 months (6 months of therapy and 3 months of follow-up).

Results. There was a statistically significant reduction in visual analog scale pain on walking just 1 month after therapy initiation (57.1±9.7 and 44.7±13.9 mm; p<0.0001) and a further significant improvement throughout the 6-month therapy. Pain did not increase after the drug was discontinued (the follow-up period was 3 months). The same pattern was observed in the assessment of the WOMAC index (pain during early therapy, 243.8±73.9; pain at the end of therapy, 137.5±78.9; stiffness, 97.8±41.1 and 57.7±38.6; functional failure, 875.8±250.4 and 525±305.7 respectively; p<0.0001). Statistically significantly improved quality of life indicators measured by EQ-5D were noted throughout the follow-up period: 0.43±0.23 at the beginning of therapy, 0.61±0.14 at its end, and 0.63±0.11 at 3 months following treatment completion (p<0.0001). By the time of therapy completion, 71.3% of the patients completely refused to take nonsteroidal anti-inflammatory drugs (NSAIDs). Both the patient and the physician evaluated the efficiency of treatment identically. By the end of therapy, 87.5% of the patients were observed to have improvement. Adverse reactions (ARs) were recorded in 10 (12.5%) patients and mainly associated with more frequent stools; ARs were not a cause of treatment interruptions or protocol deviations.

Conclusion. Diaflex has a good symptomatic and anti-inflammatory effect: the therapy statistically significantly reduces pain, stiffness, and the need for NSAIDs and improves quality of life and joint function. The drug has a good safety profile and after-effects, which is seen at least 3 months after therapy discontinuation.

1. Qvist P, Bay-Jensen AC, Christiansen C, et al. The disease modifying osteoarthritis drug (DMOAD): Is it in the horizon? Pharmacol Res. 2008 Jul;58(1):1-7. doi: 10.1016/j.phrs.2008.06.001. Epub 2008 Jun 8.

2. Bruyere O, Cooper C, Pelletier JP, et al. An algorithm recommendation for the management of knee osteoarthritis in Europe and internationally: A report from a task force of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2014 Dec;44(3):253-63. doi: 10.1016/j.semarthrit.2014.05.014. Epub 2014 May 14.

3. Martel-Pelletier J, Pelletier JP. Effects of diacerein at the molecular level in the osteoarthritis disease process. Ther Adv Musculoskelet Dis. 2010 Apr;2(2):95-104. doi: 10.1177/1759720X09359104.

4. Martin G, Bogdanowicz P, Domagala F, et al. Rhein inhibits IL-1b – induced activation of MEK/ERK pathway and DNA binding of NF-kappa B and AP-1 in chondrocytes cultured in hypoxia: potential mechanism for its disease-modifying effect in osteoarthritis. Inflammation. 2003 Aug;27(4):233-46.

5. Алексеева ЛИ, Кашеварова НГ. Диацереин при лечении остеоартрита. Медицинский Совет. 2016;(8):86-91. [Alekseeva LI, Kashevarova NG. Diacerein in the treatment of osteoarthritis. Meditsinskii Sovet. 2016; (8):86-91. (In Russ.)]. doi: 10.21518/2079-701X-2016-8-86-91

6. Pelletier JP, Lajeunesse D, Reboul P, et al. Diacerein reduces the excess synthesis of bone emodeling factors by human osteoblast cells from osteoarthritic subchondral bone. J Rheumatol. 2001 Apr;28(4):814-24.

7. Rintelen B, Neumann K, Leeb BF. A meta-analysis of controlled clinical studies with diacerein in the treatment of osteoarthritis. Arch Intern Med. 2006 Sep 25;166(17): 1899-906.

8. Fidelix TS, Soares BG, Trevisani VF. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2006 Jan25;(1):CD005117.

9. Bartels EM, Bliddal H, Schondorff PK, et al. Symptomatic efficacy and safety of diacerein in the treatment of osteoarthritis: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage. 2010 Mar;18(3):289-96. doi: 10.1016/j.joca.2009.10.006. Epub 2009 Oct 14.

10. Удовика МИ. Диацереин как препарат выбора в терапии остеоартроза коленных суставов с вторичным рецидивирущим синовитом. Научно-практическая ревматология. 2015;(53)6:614-8. [Udovika MI. Diacerein as the drug of choice in the therapy of knee osteoarthritis with secondary recurrent synovitis. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;(53)6:614-8. (In Russ.)]. doi: 10.14412/1995-4484-2015-614-618

11. Заиграева НК. Оценка эффективности препарата Артрокер при остеоартрозе коленных суставов. Современная ревматология. 2013;7(4):23-5. [Zaigraeva NK. Evaluation of the efficacy of Arthrocare for knee osteoarthrosis. Sovremennaya revmatologiya = Modern Rheumatology Journal. 2013;7(4):23-5. (In Russ.)]. doi: 10.14412/1996-7012-2013-2434

12. Dougados M, Nguen M, Berdah L, et al. Evaluation of the structure-modifying effects of Diacerhein in hip osteoarthritis. ECHODIAN, a three-year-placebo-controlled trial. Arthritis Rheum. 2001 Nov; 44(11):2539-47.

13. Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moca Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014 Feb 10;(2):CD005117. doi: 10.1002/14651858.CD005117.pub3.

14. Балабанова РМ. Применение диацереина для лечения остеоартроза крупных суставов (обзор литературы и собственный опыт). Современная ревматология. 2015;9(3):30–2. [Balabanova RM. Use of diacerein for the treatment of large joint osteoarthritis (A review of literature and the author’s own experience). Sovremennaya revmatologiya = Modern Rheumatology Journal. 2015;9(3):30–2. (In Russ.)]. doi: 10.14412/1996-7012-2015-3-30-32

15. Pavelka K, Bruyere O, Cooper C, et al. Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion- Based Report from the ESCEO. Drugs Aging. 2016 Feb;33(2):75-85. doi: 10.1007/s40266-016-0347-4.

16. Носков СМ, Красивина ИГ, Широкова КЮ и др. Диацереин в терапии больных остеоартрозом и ожирением. Тезисы VII Всероссийской конференции «Ревматология в реальной клинической практике». 2012. 37 c. [Noskov SM, Krasivina IG, Shirokova KYu, et al. Diacerein therapy in patients with osteoarthrosis and obesity. Abstracts of the VII all- Russian conference «Rheumatology in clinical practice». 2012. 37 p.]

17. Шарапова ЕП, Кашеварова НГ, Зайцева ЕМ и др. Оценка эффективности и безопасности диацереина у пациентов с остеоартрозом тазобедренных суставов. Медицинский совет. 2017;(1s):84-9. [Sharapova EP, Kashevarova NG, Zaitseva EM, et al. Evaluation of the efficacy and safety of diacerein in patients with osteoarthritis of the hip joints. Meditsinskii sovet. 2017;(1s):84-9. (In Russ.)].

18. Леушина ЕА, Симонова ОВ. Клиническая эффективность диацереина при остеоартрозе суставов кистей. Лечащий врач. 2014;(10):90-2. [Leushina EA, Simonova OV. Clinical efficacy of diacerein in osteoarthritis joints of the hands. Lechashchii vrach. 2014;(10):90-2. (In Russ.)].

19. Лила АМ, Мартынова ЛВ, Лила ВА. Диацереин в терапии остеоартрита коленных суставов: результаты сравнительного исследования. Русский медицинский журнал. 2016;(2):70-7. [Lila AM, Martynova LV, Lila VA. Diacerein in the treatment of osteoarthritis of the knee: results of a comparative study. Russkii meditsinskii zhurnal. 2016;(2):70-7. (In Russ.)].

20. Pavelka K, Trc T, Karpas K, et al. The efficacy and safety of Diacerhein in the treatment of painful osteoarthritis of the knee: a randomized, multicentre, double-blind, placebo- controlled study with primery end points at two months after the end of a three month treatment period. Arthritis Rheum. 2007 Dec;56(12):4055-64.

21. Assessment report for diacerein containing medicinal products. 28 August 2014 EMA/527347/2014. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Diacerein/ European_Commission_final_decision/WC500173144.pdf

22. Каратеев АЕ, Алексеева ЛИ. Оценка переносимости диацереина в реальной клинической практике. Результаты исследования РОКАДА (Ретроспективная Оценка Клинических Аспектов применения Диафлекса при остеоАртрозе). Научно- практическая ревматология. 2015;53(2):169–74. [Karateev AE, Alekseeva LI. Estimation of Diacerein tolerability in real clinical practice: results of the racada (retrospective assessment of clinical aspects of using Diaflex in osteoarthritis). Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2015;53(2):169–74. (In Russ.)]. doi: 10.14412/1995- 4484-2015-169-174

23. Pelletier JP, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo-controlled trial. The Diacerein Study Group. Arthritis Rheum. 2000 Oct;43(10): 2339-48.